Rho kinase inhibitors for primary open‐angle glaucoma and oc | Figure 1
%27%3e%3cg%20id=%27Group-14%27%20transform=%27translate(13.000000,%20103.176124)%27%3e%3cg%20id=%27Group-Copy-5%27%20transform=%27translate(0.000000,%20182.676124)%27%3e%3crect%20id=%27Rectangle-8%27%20fill=%27%23E2E0DE%27%20x=%270%27%20y=%270%27%20width=%2736%27%20height=%2736%27%20rx=%2718%27%3e%3c/rect%3e%3cpath%20d=%27M28,27.6503435%20C28,22.127496%2023.5228474,17.6503435%2018,17.6503435%20C12.4771525,17.6503435%208,22.127496%208,27.6503435%20M18,16.3472505%20C20.8165136,16.3472505%2023.099749,14.0640151%2023.099749,11.2475015%20C23.099749,8.43098783%2020.8165136,6.1477524%2018,6.1477524%20C15.1834863,6.1477524%2012.9002509,8.43098783%2012.9002509,11.2475015%20C12.9002509,14.0640151%2015.1834863,16.3472505%2018,16.3472505%20Z%27%20id=%27Combined-Shape%27%20fill=%27%23FFFFFF%27%20fill-rule=%27nonzero%27%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Deleted account
Some actions are only available when you log in.
Report case
Report this to our moderators
Rho kinase inhibitors for primary open‐angle glaucoma and ocular hypertension
You can view up to 4 cases without signing up Sign up for unlimited access
What are the benefits and risks of rho kinase inhibitor eye drops to treat people with either glaucoma or increased eye pressure?
Key messages
Antiglaucomatous eye drops such as latanoprost and timolol may reduce the eye pressure more compared with treatment with a rho kinase inhibitor, but the difference with timolol is small. When combining rho kinase inhibitors with different types of medicine, the eye pressure may be reduced more. People treated with a rho kinase inhibitor experience more adverse events (side effects) compared with other treatments. Future research in this area should focus on reporting disease progression (how the glaucoma gets worse over time).
We wanted to examine whether the effectiveness and safety of rho kinase inhibitor eye drops were better or worse than other medicines.
We searched for studies that compared:
‐ rho kinase inhibitor with placebo (a treatment with no therapeutic effect);
‐ rho kinase inhibitor with other types of glaucoma treatments (latanoprost and timolol).
We found 17 studies examining 4953 people aged at least 18 years diagnosed with primary open‐angle glaucoma or high eye pressure and treated with a rho kinase inhibitor. The studies varied in treatment duration from 24 hours to 12 months. They were conducted in the USA, Canada and Japan. Of the studies, 16 were funded by pharmaceutical companies and one did not provide information about potential funding sources. The effect of treatment was evaluated by measuring the eye pressure and assessing the adverse events of treatment.
The studies did not report data disease progression, but they reported data on the lowering of the pressure within the eye and adverse events. Treatment with latanoprost may be better than rho kinase inhibitor. Treatment with timolol may be slightly better than treatment with rho kinase inhibitor. Furthermore, treatment with both rho kinase inhibitor and latanoprost or timolol probably reduces the eye pressure even more. Overall, the studies reported adverse events very differently. More people treated with rho kinase inhibitors may have experienced eye‐related adverse events; however, we are not very certain about these findings. There were no serious adverse events reported for treatment with rho kinase inhibitor.
More about this case
ResolvedCommon presentation
Why you should join Figure 1
Share your knowledge with our global community of healthcare professionals
Get help from experts in your field
Learn from our library of real-world cases and quizzes
Similar cases
\ \ Immunoglobulin treatment for Kawasaki disease\ Key message\ In children with Kawasaki disease, high‐dose intravenous immunoglobulin (IVIG) regimens:\ • probably reduce the risk of coronary artery abnormalities formation compared to aspirin or medium‐ or low‐dose IVIG regimens;\ • show no clear safety concerns;\ • probably reduce the duration of fever, but there was little or no difference detected in the need for additional treatment compared to aspirin;\ • may reduce the duration of fever and need for additional treatment compared to medium‐ or low‐dose IVIG.\ What did we do?\ We searched for randomised controlled trials that compared treatment of Kawasaki disease with IVIG to treatment with another medicine or regimen. We found 31 studies with a total of 4609 participants.\ What did we find?\ We looked at studies that compared VIG with aspirin. Our results showed that children who received IVIG probably developed fewer coronary artery abnormalities than children treated with aspirin alone. Reporting of adverse effects varied between studies, but there was little or no difference in the number of adverse effects between groups. Acute coronary syndromes were poorly reported, so we cannot say if IVIG affected this. IVIG treatment probably reduced the duration of fever compared to aspirin alone. There was little or no difference in the need for additional treatment between IVIG and aspirin groups, and no study reported on the length of hospital stay. No deaths were reported in either group.\ We looked at studies that compared high‐dose IVIG regimens with medium‐ or low‐dose regimens. Our results showed that children who received high‐dose regimens probably developed fewer abnormalities. There was no apparent difference in the number of adverse effects between the high and medium‐ or low‐dose groups. Acute coronary syndromes were poorly reported, with little or no difference seen between groups. Higher‐dose regimens may reduce the duration of fever and need for additional treatment compared to medium‐ and lower‐dose regimens. We did not find a clear difference between regimens in length of hospital stay. One death was reported in one study, so we cannot say for sure if one regimen was better than another for this outcome.\ We also looked at studies that compared IVIG with prednisolone. The evidence was very uncertain.](https://app.figure1.com/case-detail/0e7d4dd3-1822-4f4a-88ad-70153b6911d7)
\ \ Bottom line\ Duloxetine and milnacipran may reduce pain in people with fibromyalgia. However, some of these people may also experience side effects, such as nausea and drowsiness. A minority of people with fibromyalgia experience symptom relief without side effects from duloxetine and milnacipran.\ Cochrane Review; 18 studies with 7903 participants. The studies were four to 27 weeks long and compared the SNRIs desvenlafaxine, duloxetine and milnacipran against placebo.\ Key results and quality of the evidence\ Duloxetine and milnacipran were better than placebo in reducing pain by 50% or more and in improving global well-being (low-quality evidence). Duloxetine and milnacipran were better than placebo in improving health-related quality of life and in reducing fatigue (low-quality evidence). Duloxetine and milnacipran were not better than placebo in reducing sleep problems (low-quality evidence). More people dropped out of the trial due to side effects with duloxetine and milnacipran than with placebo (low-quality evidence). More people reported nausea and drowsiness with duloxetine and milnacipran than with placebo (low-quality evidence). Duloxetine, milnacipran and placebo did not differ in the frequency of serious side effects experienced (very low-quality evidence).](https://app.figure1.com/case-detail/1863addd-f676-4911-8fb9-fe74196e7884)
\ \ Laser trabeculoplasty for open‐angle glaucoma\ Key messages\ • Laser trabeculoplasty may work better than topical medication (eye drops) in slowing down the progression of open‐angle glaucoma (rate of visual field loss i.e. vision loss at the edges of vision) and may be similar to modern eye drops in controlling eye pressure at a lower cost. It is not associated with any serious unwanted effects, particularly for the newer types of trabeculoplasty, such as selective laser trabeculoplasty.\ \ • Laser trabeculoplasty appears to work less well than trabeculectomy (surgery for glaucoma).\ What did we find?\ Cochrane researchers found 40 studies. These studies were mainly from Europe and the USA.\ The results were as follows:\ • Different studies found different effects on eye pressure when comparing laser trabeculoplasty with eye drops. Older studies were more likely to show a benefit of laser trabeculoplasty which may be because the eye drops in these older studies did not work as well as modern eye drops (low‐certainty evidence). Three studies showed a benefit of trabeculoplasty over eye drops for avoiding visual field progression at 24 months (argon) and 48 months (selective) (moderate‐certainty evidence, downgraded for risk bias).\ • Harmful effects were more common in the laser trabeculoplasty group and included more cases where the iris was stuck to the edge of the drainage mechanism inside the eye (peripheral anterior synaechiae) but this was seen only with older types of laser (argon) trabeculoplasty (low‐certainty evidence).\ • People receiving laser trabeculoplasty may be more likely to have pressure in the eye that is too high compared with people who had surgery (trabeculectomy) (low‐certainty evidence).\ • Surgery (trabeculectomy) may increase the risk of cataract compared with laser (very low‐certainty evidence).\ • A number of studies compared different types of laser (argon, selective, diode, excimer, pattern scanning, titanium‐sapphire, and micropulse) but with inconclusive results.\ What are the limitations of the evidence?\ Some of the studies were not masked and were not large enough to provide a reliable answer to the question. There have been changes over time in both laser and eye drops which meant that, for some outcomes, there were different effects in different studies.](https://app.figure1.com/case-detail/2594cc64-168f-4412-bccd-ebdc367cc2db)
\ \ Cyclosporine A eye drops for the treatment of dry eye\ What is the aim of this review?\ The aim of this Cochrane Review was to find out if cyclosporine A (CsA) eye drops are helpful in the treatment of dry eye. Cochrane researchers collected and analyzed all relevant studies to answer this question and found 30 studies.\ What is the key message of this review?\ It is unclear whether CsA eyedrops reduce the symptoms and signs of dry eye. People using CsA drops may experience adverse effects, such as burning or stinging.\ What was studied in the review?\ The surface of the eye is moist and covered with a thin layer of tears. When there are problems with this layer of tears, people can develop a common condition called dry eye. People with dry eye may feel discomfort, as though they have something in their eye, they may have burning sensations, or be sensitive to light. They can also have blurred vision and fluctuating vision which can affect driving and reading.\ Dry eye may develop because of underlying health problems, eye treatment or for no apparent reason. One potential underlying cause of dry eye may be inflammation. CsA drops (marketed as Restasis or Cequa) aim to improve tear production by treating this inflammation.\ What are the main results of the review?\ Cochrane researchers found 30 relevant studies. These studies took place in many different countries (Austria, Belgium, Brazil, China, Czech Republic, France, Germany, Italy, South Korea, Spain, Sweden, Thailand, Turkey, the United Kingdom, and the United States). Twelve studies were funded by the manufacturer, one was funded by a government agency, and the remaining studies did not report funding.\ Eighteen studies compared CsA combined with artificial tears versus artificial tears alone. At 6 months:\ ⇨ There was only low‐certainty evidence on whether or not CsA combined with artificial tears may help to reduce the symptoms and signs of dry eye compared with artificial tears alone.\ ⇨ There was inconsistent low‐certainty evidence as to whether or not CsA provides any benefit for tear production and stability.\ ⇨ People using CsA may have more conjunctival goblet cells (low‐certainty evidence). Conjunctival goblet cells may have a role in protecting the eye by secreting mucus (a lubricant).\ ⇨ People using CsA drops may have more treatment‐related adverse events, in particular, "burning and stinging" eyes (low‐certainty evidence).\ The remaining studies made several other comparisons of CsA in different concentrations with either placebo or artificial tears. The reporting of these studies did not allow us to understand the magnitude of effect.\ How up‐to‐date is this review?\ Cochrane researchers searched for studies that had been published up to 16 February 2018.](https://app.figure1.com/case-detail/68ffa0bf-ba61-4bce-8990-e1fc850fa81b)
Trending now
\ \ A 52-year-old man presented with a 20-minute history of chest pain radiating to the left shoulder and neck, associated with dyspnea and diaphoresis.\ He had a history of hypertension, long-term smoking, and a sedentary lifestyle.\ On physical examination, bibasilar crackles were noted on lung auscultation. An electrocardiogram (ECG) was performed in the primary care setting, and the patient was promptly referred to the emergency department.](https://app.figure1.com/case-detail/ae0fe999-6875-4474-94f0-ad823dbb9b3a)
\ \ A 28-year-old woman presented with a 3-day history of intense pruritus over the lower back. She reported no recent travel or exposure to new environments. She cares for a small kennel with approximately eight dogs rescued from the streets.\ Physical examination revealed multiple small vesicles, some clustered and others scattered, predominantly involving the lumbar region and the left gluteal area.](https://app.figure1.com/case-detail/c271070f-2bc7-4052-9895-635277e1a7d5)
\ \ A 4-month-old male infant presented with skin lesions localized to the chin for the past 3 days. Physical examination revealed multiple small pustules with surrounding inflammatory signs on the chin, along with a few scattered papules on the chest.](https://app.figure1.com/case-detail/48f41642-b9db-4089-b120-a94ee52328de)
\ \ patient in late teens presenting after a collapse, no chest pain, no previous cardiac history, no history of sudden death in family, are there any features in this ekg that would warrant further work-up or is this just a pediatric ekg?](https://app.figure1.com/case-detail/2af390e1-ace8-40ed-ba1c-98fb2d72f4c5)